Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.49 |
| ▸ | HTR2A | P28223 | 6/20 | 0.49 |
| ▸ | HTR2B | P41595 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR5A | P47898 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029713 | 0.94 | HTR2C (0.46) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL2032888 | 0.90 | KIF11 (0.42) | HTR2CHTR2AHTR2BTP53MAPT | |
| SCHEMBL2033538 | 0.89 | HTR2A (0.45) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL2029300 | 0.89 | HTR2C (0.42) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL2032521 | 0.87 | TP53 (0.46) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL2034779 | 0.87 | TP53 (0.41) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL997805 | 0.86 | ABCG2 (0.45) | ERAP1MEN1KMT2A | |
| SCHEMBL2034677 | 0.84 | MAPKAPK2 (0.40) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL2033414 | 0.84 | CHRM4 (0.36) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL2030592 | 0.84 | ERAP1 (0.38) | HTR2CHTR2AHTR2BHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | claimed |
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8952158-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-1829874-B1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8476293-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-7964726-B2 | 1-(1,3-benzodioxol-5-yl)-N-(3,5-dimethylphenyl)-1,9-dihydrospiro[ beta -carboline-4,1'-cyclopropane]-2(3H)-carboxamide; mitochondrial benzodiazepine receptor modulator; digestive system disease caused by stress: irritable bowel syndrome, ulcerative colitis, or Crohn's disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1829874-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | HTR2C 893/4885HTR2A 1711/4885HTR2B 1835/4885 |
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | HTR2C 893/4885HTR2A 1711/4885HTR2B 1835/4885 |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | HTR2C 893/4885HTR2A 1711/4885HTR2B 1835/4885 |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | SI, ALPI, SLC10A2 | HTR2C 848/4885HTR2A 1628/4885HTR2B 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.